COMPOUNDS WITH A SULPHONAMIDE GROUP AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS

• US 20090023896A1
• Filed: 06/19/2008
• Published: 01/22/2009
• Est. Priority Date: 05/31/2000
• Status: Abandoned Application

• Current Assignee: Alexander Hillisch, Annemarie Hedden, Klaus Schollkopf, Sigfrid Schwarz, Walter Elger
• Original Assignee: Alexander Hillisch, Annemarie Hedden, Klaus Schollkopf, Sigfrid Schwarz, Walter Elger
• Inventors: Schollkopf, Klaus, Hedden, Annemarie, Hillisch, Alexander, Schwarz, Sigfrid, Elger, Walter
• Application Number:
  US12/142,332
• Publication Number:
  US 20090023896A1
• Time in Patent Office: Days
• US Class Current: 530/328
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07J 41/0038 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
• CPC Class Codes: C07J 41/0044 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
• CPC Class Codes: C07J 41/005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention relates to compounds that as prodrugs and/or vehicles make it possible for an active ingredient to be taken up into erythrocytes and/or an active ingredient to bind to erythrocytes, whereby the uptake of the compounds into erythrocytes and/or the binding of the compounds to erythrocytes is made possible by a group —SO₂NR¹R², whereby R¹ and R², independently of one another, mean a hydrogen atom, an acyl group, an alkyl group, a cycloalkyl group, an aryl group, a cyano group or a hydroxy group. By the prodrugs according to the invention, active ingredients, such as endogenous substances, natural substances and synthetic substances with therapeutically valuable properties with a high “first pass” effect are made available orally to a reasonable extent or are decisively improved relative to oral activity.

Claims

1-26. -26. (canceled)

27. Compound that as a prodrug and/or vehicle makes it possible to take up an active ingredient into erythrocytes and/or to bind an active ingredient to erythrocytes, characterized in that the uptake of the compound into erythrocytes and/or the binding of the compound to erythrocytes is made possible by a group

—

SO₂NR¹R²

whereby R¹ and R², independently of one another, is a hydrogen atom, an acyl radical, an alkyl radical, a cycloalkyl radical, an aryl radical, a cyano group or a hydroxy group.

28. Compound according to claim 27, whereby the uptake of the compound into erythrocytes and/or the binding of the compound to erythrocytes is carried out via hemoglobin, membrane proteins and/or carboanhydrase.

29. Compound according to claim 27, whereby a depot of the active ingredient in the erythrocytes is formed by the uptake of the compound into erythrocytes and/or by the binding of the compound to erythrocytes, whereby an essential part of the active ingredient is present in the body in erythrocytes.

30. Compound according to claim 29, whereby the compound is enriched in the erythrocytes by a factor 10 to 1000 above the plasma level.

31. Compound according to claim 27, whereby the compound is a compound that exerts its action in the erythrocytes.

37. Compound according to claim 27, whereby the therapeutically desired action is carried out by release, especially hydrolytic cleavage, of the active ingredient that is contained in the prodrug and/or its metabolites.

40. Compound according to claim 37, whereby the spacer is a group -A-B-(O)_s, whereby s is a number 0 or 1, A stands for S, O or NR³, whereby R³ is a hydrogen atom, an alkyl radical or an acyl radical, and B is selected from an alkylene group, an arylene group, an alkylene arylene group or an alkylene arylenealkylene group, which optionally are substituted.